Bluebird bio Inc (BLUE) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Bluebird bio Inc (BLUE) has a cash flow conversion efficiency ratio of 0.751x as of March 2025. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-43.44 Million) by net assets ($-57.87 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see Bluebird bio Inc market capitalisation for the company's overall valuation and market capitalisation.
Bluebird bio Inc - Cash Flow Conversion Efficiency Trend (2011–2024)
This chart illustrates how Bluebird bio Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Bluebird bio Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Bluebird bio Inc ranked by their cash flow conversion efficiency. Explore how high is Bluebird bio Inc's earnings quality to measure how well operating cash flow supports reported net income.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Quartiers Properties AB
ST:QUART
|
0.048x |
|
Sietel Ltd
AU:SSL
|
-0.001x |
|
TsannKuen (China) Enterprise Co. Ltd
SHE:200512
|
-0.016x |
|
Maison Antoine Baud Société Anonyme
PA:MLMAB
|
N/A |
|
Senzime AB
ST:SEZI
|
-0.081x |
|
Green Cross Medical Science Corporation
KQ:142280
|
-0.013x |
|
Enzymatica publ AB
ST:ENZY
|
-0.085x |
|
Iskandar Waterfront City Bhd
KLSE:1589
|
0.015x |
Annual Cash Flow Conversion Efficiency for Bluebird bio Inc (2011–2024)
The table below shows the annual cash flow conversion efficiency of Bluebird bio Inc from 2011 to 2024. View BLUE share price today for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $-31.53 Million | $-260.02 Million | 8.246x | +782.46% |
| 2023-12-31 | $194.54 Million | $-235.05 Million | -1.208x | +32.79% |
| 2022-12-31 | $196.34 Million | $-352.95 Million | -1.798x | -5.85% |
| 2021-12-31 | $374.28 Million | $-635.64 Million | -1.698x | -389.27% |
| 2020-12-31 | $1.36 Billion | $-470.35 Million | -0.347x | +20.97% |
| 2019-12-31 | $1.28 Billion | $-564.38 Million | -0.439x | -100.26% |
| 2018-12-31 | $1.89 Billion | $-413.43 Million | -0.219x | -26.91% |
| 2017-12-31 | $1.62 Billion | $-280.55 Million | -0.173x | +20.77% |
| 2016-12-31 | $869.44 Million | $-189.65 Million | -0.218x | -88.48% |
| 2015-12-31 | $850.50 Million | $-98.43 Million | -0.116x | +4.76% |
| 2014-12-31 | $491.26 Million | $-59.69 Million | -0.122x | -142.41% |
| 2013-12-31 | $151.67 Million | $43.45 Million | 0.286x | -24.11% |
| 2012-12-31 | $-55.75 Million | $-21.04 Million | 0.377x | +72.13% |
| 2011-12-31 | $-55.71 Million | $-12.22 Million | 0.219x | -- |
About Bluebird bio Inc
bluebird bio, Inc., a biotechnology company, researches, develops, and commercializes gene therapies for curative severe genetic diseases in the United States. The company's product candidates for severe genetic diseases include ZYNTEGLO (betibeglogene autotemcel) for the treatment of transfusion-dependent ß-thalassemia; LYFGENIA (lovotibeglogene autotemcel) for the treatment of sickle cell disea… Read more